Amorphous nilotinib microparticles and uses thereof
Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.
1. A treatment regimen for treating a proliferative disorder in a patient in need thereof, the regimen comprising:
(a) administering to the patient a first dose, the first dose comprising a standard dosage of a proton pump inhibitor; and
(b) within 10 hours after the first dose, administering a second dose to the patient, the second dose comprising a pharmaceutical composition comprising an amorphous solid dispersion, the amorphous solid dispersion comprising nilotinib and one or more polymers, wherein the one or more polymers comprises an anionic polymer comprising phthalate functionality;
wherein the nilotinib and the anionic polymer comprising phthalate functionality are present in the amorphous solid dispersion in a w/w ratio of 20:80 to 95:5 (nilotinib:polymer);
wherein the amount of nilotinib in the second dose is 50 to 80% less than a dose required for delivering a therapeutically effective amount of nilotinib in the fasted state using a conventional immediate-release crystalline nilotinib formulation; and
wherein the second dose provides a therapeutically relevant exposure of nilotinib to the patient.
2. The treatment regimen of claim 1 , wherein the proliferative disorder is Philadelphia chromosome positive chronic myeloid leukemia.
3. The treatment regimen of claim 1 , wherein the first dose comprises a standard dosage of a proton pump inhibitor selected from rabeprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, dexlansoprazole, or a combination thereof.
4. The treatment regimen of claim 1 , wherein the first dose comprises a standard dosage of omeprazole.
5. The treatment regimen of claim 1 , wherein the second dose is administered within 4 hours after the first dose.
6. The treatment regimen of claim 1 , wherein the second dose is administered within 2 hours after the first dose.
7. The treatment regimen of claim 1 , wherein the first dose and the second dose are administered concurrently.
8. The treatment regimen of claim 1 , wherein the nilotinib is present in the amorphous solid dispersion as nilotinib free base or nilotinib hydrochloride.
9. The treatment regimen of claim 1 , wherein the anionic polymer comprising phthalate functionality includes hydroxypropyl methylcellulose phthalate.
10. The treatment regimen of claim 1 , wherein the anionic polymer comprising phthalate functionality includes polyvinyl acetate phthalate.
11. The treatment regimen of claim 1 , wherein the amorphous solid dispersion includes one or more functional components selected from the group consisting of antioxidants, wetting agents, and solubilizers.
12. The treatment regimen of claim 1 , wherein the amorphous solid dispersion includes one or more solubilizers.
13. The treatment regimen of claim 12 , wherein the one or more solubilizers comprises polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
14. The treatment regimen of claim 12 , wherein the one or more solubilizers comprises d-α-tocopherol acid polyethylene glycol (PEG) 1000 succinate.
15. The treatment regimen of claim 1 , wherein the amorphous solid dispersion consists essentially of nilotinib and the anionic polymer comprising phthalate functionality.
16. The treatment regimen of claim 1 , wherein the amorphous solid dispersion consists essentially of nilotinib and hydroxypropyl methylcellulose phthalate.
17. The treatment regimen of claim 1 , wherein the amorphous solid dispersion consists essentially of nilotinib and polyvinyl acetate phthalate.
18. The treatment regimen of claim 1 , wherein the nilotinib and the anionic polymer comprising phthalate functionality are present in the amorphous solid dispersion in a w/w ratio of 25:75 to 90:10 (nilotinib:polymer).
19. The treatment regimen of claim 1 , wherein the pharmaceutical composition comprises the amorphous solid dispersion and one or more pharmaceutically acceptable additives.
20. The treatment regimen of claim 19 , wherein the one or more pharmaceutically acceptable additives includes one or more solubilizers.
21. The treatment regimen of claim 20 , wherein the one or more solubilizers comprises polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
22. The treatment regimen of claim 20 , wherein the one or more solubilizers comprises d-α-tocopherol acid polyethylene glycol (PEG) 1000 succinate.